Brief: Unity Biotechnology Announces Positive 24-Week Data From Phase 2 Behold Study Of UBX1325
01/11/2022 11:01
Nov 1 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY ANNOUNCES POSITIVE 24-WEEK DATA FROM
PHASE 2
BEHOLD STUDY OF UBX1325 IN PATIENTS WITH DIABETIC MACULAR EDEMA
Source text for Eikon: ID:nGNX2ZFlqr
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force